RGX-104

• Description :

  RGX-104 is an orally bioavailable and potent liver-X nuclear hormone receptor (LXR) agonist that modulates innate immunity via transcriptional activation of the ApoE gene.

• Product Name Alternative :

  Abequolixron

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  LXR

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/RGX-104_free_Acid.html

• Purity :

  99.76

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(O)CC1=CC=CC(OCC[C@H](N(CC2=CC=CC(C(F)(F)F)=C2Cl)CC(C3=CC=CC=C3)C4=CC=CC=C4)C)=C1

• Molecular Formula :

  C34H33ClF3NO3

• Molecular Weight :

  596.08

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Tavazoie MF, et al. LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. Cell. 2018 Feb 8;172 (4) :825-840.e18.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• CAS Number :

  [610318-54-2]